Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer()

CDK4/6 inhibitors have an established role in the treatment of hormone receptor positive HER2-negative advanced breast cancer. All studies conducted in metastatic breast cancer showed a benefit in delaying progression when added to standard endocrine therapy, regardless of therapy line, pretreatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Loibl, Sibylle, Furlanetto, Jenny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097805/
https://www.ncbi.nlm.nih.gov/pubmed/34930649
http://dx.doi.org/10.1016/j.breast.2021.12.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097805/
https://www.ncbi.nlm.nih.gov/pubmed/34930649
http://dx.doi.org/10.1016/j.breast.2021.12.008

Ejemplares similares